

NET ASSET VALUE – 31 August 2024

On the 31 August 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,360 million and NAV per share was SEK 55.85.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development				
Prokarium	42%	473	6.06	10.9%
Xspray Pharma	18%	303	3.88	7.0%
Xintela	56%	205	2.63	4.7%
Empros Pharma	79%	204	2.62	4.7%
KAHR Medical	31%	193	2.47	4.4%
Atrogi	37%	176	2.25	4.0%
Lipum	57%	148	1.90	3.4%
Microbiotica	11%	135	1.73	3.1%
Mendus	24%	103	1.32	2.4%
Geneos Therapeutics	12%	98	1.26	2.3%
Toleranzia	58%	58	0.75	1.3%
EpiEndo Pharmaceuticals	9%	56	0.72	1.3%
Synerkine Pharma	43%	52	0.67	1.2%
AnaCardio	19%	52	0.66	1.2%
Egetis Therapeutics	2%	42	0.53	1.0%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Vitara Biomedical	5%	27	0.35	0.6%
Sixera Pharma	23%	26	0.33	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Amarna Therapeutics	60%	11	0.15	0.3%
Strike Pharma	16%	9	0.11	0.2%
Total		2,419	30.98	55.5%
Commercial Growth				
NorthX Biologics	92%	189	2.42	4.3%
Symcel	31%	169	2.16	3.9%
A3P Biomedical	8%	75	0.96	1.7%
Chromafora	31%	73	0.93	1.7%
Provell Pharmaceuticals	72%	68	0.87	1.6%
Nanologica	39%	42	0.54	1.0%
Frontier Biosolutions	2%	19	0.24	0.4%
Bohus Biotech	45%	17	0.21	0.4%
Total		651	8.34	14.9%
Limited Partnerships, total				
		87	1.11	2.0%

Assets related to portfolio companies		398	5.10	9.1%
Other assets and liabilities		805	10.32	18.5%
NAV		4 360	55.85	100.0%
<i>* indirect shares in Provell Pharmaceuticals</i>				

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[NET ASSET VALUE – 31 August 2024](#)